ArticlePloS one2015

Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study.

Ariel Hammerman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.